Tuesday, July 12, 2016 5:02:00 AM PDT | VentureDeal
Fort Lauderdale, Florida -- Medical device technology company Vigilant Biosciences has received $5 million in its second round of institutional venture capital financing.
Vigilant has created point of care and lab-based solutions to assist in the diagnosis of oral cancer. Investors in the financing included White Owl Capital, venVelo and other undisclosed investors. The company said it would use the funding to "support numerous commercial and development efforts." It also plans to launch its OncAlert Oral Cancer product line internationally with the funding.
Email Page | Print Page
Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?
Start your Free 14 Day Trial now – no obligation or credit card required.
